International Journal of Medical and Health Research

ISSN: 2454-9142

Vol. 5, Issue 1 (2019)

Comparative study of efficacy and safety of topical 0.005% Calcipotriol and topical 0.1% Tazarotene in patients of Palmo-plantar psoriasis

Author(s): Dr. Ashok Kumar Keer, Dr. MP Shukla, Dr. Dileep Dandotiya
Abstract: Background: Topical therapies are the first line of treatment for patients with palmoplanter psoriasis affecting both palms and soles. Although in use for more than a decade yet we could not find any reports of studies directly comparing calcipotriol and tazarotene. Aim: To evaluate the comparative efficacy and safety of calcipotriol and tazarotene in the treatment of palmoplanter psoriasis. Methods: This was an observational, open level, two groups comparative, longitudinal follow up(every 4week), 12-week study using calcipotriol 0.005% ointment applied twice daily (group A) versus0.1% ointment tazarotene (group B) applied once daily, each group having 40 patients. Efficacy was determined by the assessment of target psoriatic lesions under evaluation by using the severity scale (0-3) of erythema, scaling, fissuring and infiltration (ESIF score). Evaluation was done at baseline (0 week), 4 weeks, 8 weeks, and 12 weeks of treatment. At the end of 12 weeks reduction in the ESIF score was compared in patients of both groups. Safety of this study was evaluated by comparing the adverse drug reaction in each group. Results: Forty-one patients in group A (Calcipotriol group) completed the study. In this group reduction in ESI score was significant at 12 weeks in patients treated with topical calcipotriol, producing moderate-to-marked improvement (P< 0.0001). In group B (Tazarotene group), improvement was comparable in lesions treated with calcipotriol at the end of 12 weeks after the topical treatment by 0.1% tazarotene. Adverse effects noted were mild - in the form of burning, pruritus, and irritation - and were observed more often in the lesions treated with tazarotene as compared to those in the lesions treated with calcipotriol, but the difference was not statistically significant. However, none of the patients discontinued the therapy because of adverse events. Conclusion: In conclusion, topical 0.005% Calcipotriol and topical 0.1% Tazarotene both are efficacious in treatment of palmoplanter with almost same safety profile.
Pages: 41-43  |  500 Views  133 Downloads
library subscription